Losartan to Improve Hip Microfracture (NCT04212650) | Clinical Trial Compass
TerminatedPhase 1/2
Losartan to Improve Hip Microfracture
Stopped: redesigned trial using another placebo controlled drug
United States1 participantsStarted 2020-08-07
Plain-language summary
Phase I/IIA randomized, double-blind, placebo-controlled clinical trial to assess safety and efficacy of oral losartan for improving cartilage repair following microfracture to treat focal cartilage defects during hip arthroscopy.
Who can participate
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Underwent primary hip arthroscopy
* Underwent baseline quantitative MRI at The Steadman Clinic (TSC)
* Single, localized, grade 3 or 4 cartilage lesion of the acetabulum or femoral head treated with Bone Marrow Stimulation (BMS; i.e. microfracture)
* Aged 18-60 at time of surgery
* Tonnis grade 1 or less
Exclusion Criteria:
* Two or more cartilage lesions of grade 3 or 4
* Less than 2 mm of minimal hip joint space
* Osteoarthritis or diffuse change of cartilage
* Non-English speaking
* Prior hip surgery on operative hip
* Pre-existing bony deformity caused by previous fracture(s)
* Synovial chondromatosis
* Pigmented Villonodular Synovitis (PVNS)
* Dysplasia (center edge angle \<20 degrees)
* History of Avascular Necrosis (AVN), Perthes disease, or slipped capital femoral epiphysis (SCFE)
* Inflammatory arthritis or other arthritis caused by autoimmune disease
* Patients allergic to any active or inactive ingredient of losartan
* Patients taking medication with known losartan interaction, including phenobarbital, rifampin, and fluconazole.
* Subjects that are currently taking losartan
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Treatment-Emergent Adverse Events
Timeframe: Drug related adverse events will be monitored during the medication phase (post-op days 2-31) and orthopaedic-related health and function will be monitored for the entire study duration (18 months).